BRPI0603490A - processo para vacina recombinante contra a leishmaniose visceral canina contendo o antìgeno recombinante a2 e que permite a distinção sorológica entre animais vacinados de animais infectados - Google Patents

processo para vacina recombinante contra a leishmaniose visceral canina contendo o antìgeno recombinante a2 e que permite a distinção sorológica entre animais vacinados de animais infectados

Info

Publication number
BRPI0603490A
BRPI0603490A BRPI0603490-0A BRPI0603490A BRPI0603490A BR PI0603490 A BRPI0603490 A BR PI0603490A BR PI0603490 A BRPI0603490 A BR PI0603490A BR PI0603490 A BRPI0603490 A BR PI0603490A
Authority
BR
Brazil
Prior art keywords
animals
recombinant
vaccinated
vaccine against
against canine
Prior art date
Application number
BRPI0603490-0A
Other languages
English (en)
Inventor
Ana Paula Salles Mou Fernandes
Christiane De Freitas Abrantes
Eduardo Antonio Ferraz Coelho
Ricardo Tostes Gazzielli
Original Assignee
Univ Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minas Gerais filed Critical Univ Minas Gerais
Priority to BRPI0603490-0A priority Critical patent/BRPI0603490B1/pt
Priority to US12/374,626 priority patent/US8734815B2/en
Priority to PCT/BR2007/000248 priority patent/WO2008009088A2/en
Priority to MX2009000717A priority patent/MX2009000717A/es
Priority to EP07800392.8A priority patent/EP2061506B1/en
Publication of BRPI0603490A publication Critical patent/BRPI0603490A/pt
Priority to GT200900012A priority patent/GT200900012A/es
Priority to CO09017840A priority patent/CO6150186A2/es
Priority to US14/288,361 priority patent/US8968749B2/en
Publication of BRPI0603490B1 publication Critical patent/BRPI0603490B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PROCESSO PARA VACINA RECOMBINANTE CONTRA A LEISHMANIOSE VISCERAL CANINA CONTENDO O ANTìGENO RECOMBINANTE A2 E QUE PERMITE A DISTINçãO SOROLóGICA ENTRE ANIMAIS VACINADOS DE ANIMAIS INFECTADOS. A presente invenção refere-se à vacina recombinante contra a leishmaniose visceral canina contendo a proteína recombinante A2 e saponina, como adjuvante, e que permite a distinção entre animais vacinados e infectados por meio de testes de ELISA ou imunofluorescência convencionais que empregam antígenos de formas promastigotas de Leishmania. A vacina objeto do presente pedido caracteriza-se pela manutenção da soronegatividade dos cães aos testes sorológicas convencionais após a administração de cada uma das doses vacinais, tornando possível a diferenciação sorológica entre os animais vacinados com A2 da forma amastigota de Leishmania daqueles infectados.
BRPI0603490-0A 2006-07-21 2006-07-21 Vacina recombinante contra a leishmaniose visceral canina BRPI0603490B1 (pt)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BRPI0603490-0A BRPI0603490B1 (pt) 2006-07-21 2006-07-21 Vacina recombinante contra a leishmaniose visceral canina
US12/374,626 US8734815B2 (en) 2006-07-21 2007-07-20 Vaccine composition and immunization method
PCT/BR2007/000248 WO2008009088A2 (en) 2006-07-21 2007-07-20 Vaccine composition and immunization method
MX2009000717A MX2009000717A (es) 2006-07-21 2007-07-20 Composicion para vacuna y metodo para inmunizacion.
EP07800392.8A EP2061506B1 (en) 2006-07-21 2007-07-20 Vaccine composition and immunization method
GT200900012A GT200900012A (es) 2006-07-21 2009-01-20 Composicion de vacuna y metodo de inmunizacion
CO09017840A CO6150186A2 (es) 2006-07-21 2009-02-23 Composicion de vacuna y metodo de inmunizacion
US14/288,361 US8968749B2 (en) 2006-07-21 2014-05-27 Vaccine composition and immunization method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0603490-0A BRPI0603490B1 (pt) 2006-07-21 2006-07-21 Vacina recombinante contra a leishmaniose visceral canina

Publications (2)

Publication Number Publication Date
BRPI0603490A true BRPI0603490A (pt) 2008-03-11
BRPI0603490B1 BRPI0603490B1 (pt) 2018-04-24

Family

ID=38957122

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0603490-0A BRPI0603490B1 (pt) 2006-07-21 2006-07-21 Vacina recombinante contra a leishmaniose visceral canina

Country Status (7)

Country Link
US (1) US8734815B2 (pt)
EP (1) EP2061506B1 (pt)
BR (1) BRPI0603490B1 (pt)
CO (1) CO6150186A2 (pt)
GT (1) GT200900012A (pt)
MX (1) MX2009000717A (pt)
WO (1) WO2008009088A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015029002A1 (pt) * 2013-09-02 2015-03-05 Universidade Federal De Minas Gerais - Ufmg Gene modificado de leishmania ssp., processo para obtenção de proteína e uso como antígeno em composição vacinal ou em imunodiagnóstico

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BR112020016474A2 (pt) * 2018-02-13 2020-12-15 University Of Iowa Research Foundation Imunoterapia de leishmaniose

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US570591A (en) 1896-11-03 Max ams
BR9302386A (pt) 1993-06-17 1995-01-17 Univ Rio De Janeiro Composição contendo frações de células de leishmania, denominadas antígeno FML "fucose mannose ligand" ou "ligante de fucose-manose", uso de antígeno FML e de suas subfrações e componentes para as aplicações em imunodiagnóstico específico da leishmaniose visceral humana e animal, para aplicações em vacinação, tratamento ou imunoterapia contra a leishmaniose visceral humana e canina
PT716697E (pt) 1993-09-03 2003-08-29 Univ Mcgill Genes e proteinas de leishmania expressos diferencialmente
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US20010034330A1 (en) * 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
US6875584B1 (en) * 1999-03-02 2005-04-05 University Of Georgia Research Foundation, Inc. Prophylactic and therapeutic immunization against protozoan infection and disease
AU2001277961A1 (en) * 2000-08-07 2002-02-18 Antigenics, Llc Compositions comprising heat shock proteins or alpha(2)macroglobulin, antigenic molecules and saponins, and methods of use thereof
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002303135A1 (en) * 2001-03-13 2002-09-24 Corixa Corporation Heterologous fusion protein constructs comprising a leishmania antigen
MXPA03008832A (es) * 2001-03-29 2004-05-05 Univ Mcgill Vacunas contra leishmania.
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
ES2447843T3 (es) * 2002-10-29 2014-03-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polip�ptidos de Lutzomyia longipalpis y m�todos de uso
MXPA05008051A (es) * 2003-01-29 2005-09-21 Pfizer Prod Inc Vacunas caninas contra bordetella bronchiseptica.
JP2006110915A (ja) * 2004-10-15 2006-04-27 Ricoh Co Ltd 印刷装置および印刷システム
US20090028932A1 (en) * 2005-04-15 2009-01-29 Wilson Mary E Vaccine formulations for leishmania
BRPI0912768A2 (pt) * 2008-05-21 2016-05-17 Infectious Disease Res Inst vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015029002A1 (pt) * 2013-09-02 2015-03-05 Universidade Federal De Minas Gerais - Ufmg Gene modificado de leishmania ssp., processo para obtenção de proteína e uso como antígeno em composição vacinal ou em imunodiagnóstico

Also Published As

Publication number Publication date
GT200900012A (es) 2010-06-22
US20110008391A1 (en) 2011-01-13
EP2061506A2 (en) 2009-05-27
US8734815B2 (en) 2014-05-27
EP2061506A4 (en) 2010-04-28
WO2008009088A2 (en) 2008-01-24
MX2009000717A (es) 2009-06-17
CO6150186A2 (es) 2010-04-20
WO2008009088A3 (en) 2008-05-08
EP2061506B1 (en) 2015-10-21
BRPI0603490B1 (pt) 2018-04-24
WO2008009088B1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
BR112015009070A2 (pt) proteína de fusão ou coquetel de antígenos; uso de uma proteína de fusão ou um coquetel de antígenos; vacina; e método para imunizar um animal, que inclui um ser humano, contra tuberculose causada por microbactérias virulentas
Fujiwara et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis
AR072378A1 (es) Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos.
HRP20211451T1 (hr) Novi cjepivni pripravci protiv virusa svinjske epidemijske dijareje
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
Martins et al. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis
UA114502C2 (uk) Вакцина mycoplasma hyopneumoniae
BRPI0418317A (pt) vacina de aumento de crescimento à base de epitopo de neutralização
Chen et al. Protective efficacy of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) adjuvated with recombinant IL-15 and IL-21 against experimental toxoplasmosis in mice
Hernandez-Davies et al. Administration of multivalent influenza virus recombinant hemagglutinin vaccine in combination-adjuvant elicits broad reactivity beyond the vaccine components
Sánchez et al. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection
BRPI0603490A (pt) processo para vacina recombinante contra a leishmaniose visceral canina contendo o antìgeno recombinante a2 e que permite a distinção sorológica entre animais vacinados de animais infectados
Martin-Martin et al. Kinetics of anti-Phlebotomus perniciosus saliva antibodies in experimentally bitten mice and rabbits
Hoxie et al. A recombinant N2 neuraminidase-based CpG 1018® adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters
Lagunes et al. Potential effects on Rhipicephalus microplus tick larvae fed on calves immunized with a Subolesin peptide predicted by epitope analysis.
BRPI0800485A8 (pt) vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
Abanades et al. Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis
BR112012011395B1 (pt) Uso de uma fonte de l3 e/ou l5 como uma vacina ou como um diagnóstico para uma doença parasítica
CR20120301A (es) Procedimiento de identificación de animales vacunados frente a brucella
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
AR093530A1 (es) Adyuvante de vacunacion, preparacion, y vacunas que lo contienen
EA200701801A1 (ru) Применение модифицированных поксвирусов для быстрой индукции иммунитета против поксвирусных или других инфекционных агентов
Ruan et al. Interleukin 8 enhances the immune response of ducks to avian influenza vaccine.
Harpreet et al. Immunoprophylactic potential of a cocktail of three low molecular weight antigens of leishmania donovani along with various adjuvants against experimental visceral leishmaniasis
Kharb Development of ELISA techniques for haemorrhagic septicaemia

Legal Events

Date Code Title Description
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 1940 DE 11/03/2008, QUANTO AO ITEM (72).

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA 7A ANUIDADE DE ACORDO COM A TABELA VIGENTE, REFERENTE A GUIA DE RECOLHIEMNTO 221206935817, E COMPROVAR O RECOLHIMENTO DA 5A ANUIDADE.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]